Wenlong Ren

Yunnan Key Laboratory Of Breast Cancer Precision Medicine
Kunming, 650000, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

DHL-11, a novel prieurianin-type limonoid isolated from Munronia henryi, targeting IMPDH2 to inhibit triple-negative breast cancer.

DHL-11, a novel prieurianin-type limonoid isolated from Munronia henryi, targeting IMPDH2 to inhibit triple-negative breast cancer.

Journal: Acta pharmaceutica Sinica. B

Published: March 10, 2025

A novel peptide 66CTG stabilizes Myc proto-oncogene protein to promote triple-negative breast cancer growth.

A novel peptide 66CTG stabilizes Myc proto-oncogene protein to promote triple-negative breast cancer growth.

Journal: Signal transduction and targeted therapy

Published: January 22, 2025

Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer.

Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: October 21, 2024

TNFAIP2 promotes HIF1α transcription and breast cancer angiogenesis by activating the Rac1-ERK-AP1 signaling axis.

TNFAIP2 promotes HIF1α transcription and breast cancer angiogenesis by activating the Rac1-ERK-AP1 signaling axis.

Journal: Cell death & disease

Published: July 02, 2024

CDK9 targeting PROTAC L055 inhibits ERα-positive breast cancer.

CDK9 targeting PROTAC L055 inhibits ERα-positive breast cancer.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: March 12, 2024

Toxoflavin analog D43 exerts antiproliferative effects on breast cancer by inducing ROS-mediated apoptosis and DNA damage.

Toxoflavin analog D43 exerts antiproliferative effects on breast cancer by inducing ROS-mediated apoptosis and DNA damage.

Journal: Scientific reports

Published: October 04, 2023

Integrin β4 promotes DNA damage-related drug resistance in triple-negative breast cancer via TNFAIP2/IQGAP1/RAC1.

Integrin β4 promotes DNA damage-related drug resistance in triple-negative breast cancer via TNFAIP2/IQGAP1/RAC1.

Journal: eLife

Published: October 03, 2023

Histone Deacetylase Inhibitors (HDACi) Promote KLF5 Ubiquitination and Degradation in Basal-like Breast Cancer.

Histone Deacetylase Inhibitors (HDACi) Promote KLF5 Ubiquitination and Degradation in Basal-like Breast Cancer.

Journal: International journal of biological sciences

Published: July 25, 2021

YB-1 is a positive regulator of KLF5 transcription factor in basal-like breast cancer.

YB-1 is a positive regulator of KLF5 transcription factor in basal-like breast cancer.

Journal: Cell death and differentiation

Published: June 06, 2021

Showing 1-9 of 9

Last Updated: 09/26/2026